Clinical trials

Condition   Drug Name  
Study Adalimumab in psoriatic arthritis: The ADEPT (ADalimumab Effectiveness in Psoriatic arthritis Trial)
Design Randomized; Double-blind
Treatment Regimen Adalimumab, 40 mg 1x/2 wks x 24 wks; Placebo
Conclusions Improvement in the Dermatology-specific Quality of Life scores were seen in psoriasis arthritis patients with Psoriasis Area and Severity Index 75 and 100 responses after treatment with adalimumab
Reference(s) PASI 100 is associated with better dermatology-specific patient reported outcomes compared with PASI 75-99 in adalimumab-treated patients with psoriatic arthritis: Subanalysis of ADEPT
16th Congr Eur Acad Dermatol Venereol (EADV) (May 16 2007 , Vienna) 2007:Abst P1107.
Author and Affiliation Gladman, D., Mease, P., Ritchlin, C., Okun, M.